Table 1

 Efficacy of disease modifying antirheumatic drugs against rheumatoid arthritis activity and structural involvement as a function of disease duration, as assessed in November 2003

DMARDEfficacy against inflammation*Efficacy against structural involvement*
<6 m<1 y<2 y<5 yAny duration<6 m<1 y<2 y<5 yAny duration
*Level of evidence as defined by Shekelle et al.7A: based on evidence from at least one randomised controlled trial (RCT) or meta-analyses of RTC. B: based on evidence from at least one controlled but not randomised trial, another type of experimental study, or extrapolated recommendations from RCT or meta-analyses. C: based on non-experimental descriptive studies—for example, comparative, correlational and case–control studies, which are extrapolated from RCT, non-RTC, or other experimental studies. D: based on expert committee reports or clinical experience of respected authorities or both, or those in levels B and C.
DMARD, disease modifying antirheumatic drug; m, months; y, years.
HydroxychloroquineAAA
Gold saltsAAAAAA
AuranofinAAA
D-PenicillamineAAA
TioproninB
MinocyclineAA
SulfasalazineAAAA
AzathioprineAC
CiclosporineCCCCACCCA
MethotrexateAAA
LeflunomideBADA
EtanerceptAAAA
InfliximabDDADDA
AdalimumabDADA
AnakinraAA
CorticosteroidsAAAAAA